Polymyositis and dermatomyositis epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
| Line 12: | Line 12: | ||
===Prevalence=== | ===Prevalence=== | ||
*The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide.<ref name=" | *The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide.<ref name="SchiffenbauerFaghihi-Kashani2018">{{cite journal|last1=Schiffenbauer|first1=Adam|last2=Faghihi-Kashani|first2=Sara|last3=O’Hanlon|first3=Terrence P.|last4=Flegel|first4=Willy A.|last5=Adams|first5=Sharon D.|last6=Targoff|first6=Ira N.|last7=Oddis|first7=Chester V.|last8=Ytterberg|first8=Steven R.|last9=Aggarwal|first9=Rohit|last10=Christopher-Stine|first10=Lisa|last11=Shamim|first11=Ejaz A.|last12=Dellaripa|first12=Paul F.|last13=Danoff|first13=Sonye K.|last14=Mammen|first14=Andrew|last15=Miller|first15=Frederick W.|title=The impact of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis|journal=Seminars in Arthritis and Rheumatism|year=2018|issn=00490172|doi=10.1016/j.semarthrit.2018.02.003}}</ref> | ||
*In 2003, the prevalence of polymyositis and dermatomyositis was estimated to be 21.5 cases per 100,000 individuals in Quebec.<ref name="BernatskyJoseph20082">{{cite journal|last1=Bernatsky|first1=S|last2=Joseph|first2=L|last3=Pineau|first3=C A|last4=Belisle|first4=P|last5=Boivin|first5=J F|last6=Banerjee|first6=D|last7=Clarke|first7=A E|title=Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences|journal=Annals of the Rheumatic Diseases|volume=68|issue=7|year=2008|pages=1192–1196|issn=0003-4967|doi=10.1136/ard.2008.093161}}</ref> | *In 2003, the prevalence of polymyositis and dermatomyositis was estimated to be 21.5 cases per 100,000 individuals in Quebec.<ref name="BernatskyJoseph20082">{{cite journal|last1=Bernatsky|first1=S|last2=Joseph|first2=L|last3=Pineau|first3=C A|last4=Belisle|first4=P|last5=Boivin|first5=J F|last6=Banerjee|first6=D|last7=Clarke|first7=A E|title=Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences|journal=Annals of the Rheumatic Diseases|volume=68|issue=7|year=2008|pages=1192–1196|issn=0003-4967|doi=10.1136/ard.2008.093161}}</ref> | ||
*In 2010, the prevalence of polymyositis and dermatomyositis was estimated to be 13.2 cases per 100,000 individuals in Japan.<ref name="AirioKautiainen2006">{{cite journal|last1=Airio|first1=A.|last2=Kautiainen|first2=H.|last3=Hakala|first3=M.|title=Prognosis and mortality of polymyositis and dermatomyositis patients|journal=Clinical Rheumatology|volume=25|issue=2|year=2006|pages=234–239|issn=0770-3198|doi=10.1007/s10067-005-1164-z}}</ref> | *In 2010, the prevalence of polymyositis and dermatomyositis was estimated to be 13.2 cases per 100,000 individuals in Japan.<ref name="AirioKautiainen2006">{{cite journal|last1=Airio|first1=A.|last2=Kautiainen|first2=H.|last3=Hakala|first3=M.|title=Prognosis and mortality of polymyositis and dermatomyositis patients|journal=Clinical Rheumatology|volume=25|issue=2|year=2006|pages=234–239|issn=0770-3198|doi=10.1007/s10067-005-1164-z}}</ref> | ||
Revision as of 16:18, 11 April 2018
|
Polymyositis and dermatomyositis Microchapters |
|
Differentiating Polymyositis and dermatomyositis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polymyositis and dermatomyositis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Polymyositis and dermatomyositis epidemiology and demographics |
|
FDA on Polymyositis and dermatomyositis epidemiology and demographics |
|
CDC on Polymyositis and dermatomyositis epidemiology and demographics |
|
Polymyositis and dermatomyositis epidemiology and demographics in the news |
|
Blogs on Polymyositis and dermatomyositis epidemiology and demographics |
|
Risk calculators and risk factors for Polymyositis and dermatomyositis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Epidemiology and Demographics
Incidence
- The incidence of polymyositis and dermatomyositis is approximately 2 per 100,000 individuals worldwide.[1][2]
- In 2010, the incidence of polymyositis and dermatomyositis was estimated to be 1-1.3 cases per 100,000 individuals in Japan annually.[3]
- In 1970, the age‐adjusted annual incidence of polymyositis was 5 cases per 100,000 individuals in USA hospital‐based retrospective study.[4]
Prevalence
- The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide.[5]
- In 2003, the prevalence of polymyositis and dermatomyositis was estimated to be 21.5 cases per 100,000 individuals in Quebec.[6]
- In 2010, the prevalence of polymyositis and dermatomyositis was estimated to be 13.2 cases per 100,000 individuals in Japan.[3]
Case-fatality rate/Mortality rate
- The 5-year survival rate for polymyositis is 75% and for dermatomyositis is 63%.[3]
- The median survival for polymyositis is 11.0 years and that for dermatomyositis is 12.3 years.[3]
Age
- Dermatomyositis has a bimodal pattern, commonly affects both children and adults over 50 years old.[7][2]
- Polymyositis commonly affects adults after second decades of their lives and it is rare among children.[7][8]
Race
- There is no racial predilection to polymyositis and dermatomyositis.
Gender
- Females are more commonly affected by polymyositis and dermatomyositis than males. The female to male ratio is approximately 2 to 1.[7]
Region
- Prevalence of polymyositis and dermatomyositis are lower in young rural men and higher in older urban women.[9]
References
- ↑ Jacobson DL, Gange SJ, Rose NR, Graham NM (September 1997). "Epidemiology and estimated population burden of selected autoimmune diseases in the United States". Clin. Immunol. Immunopathol. 84 (3): 223–43. PMID 9281381.
- ↑ 2.0 2.1 Khan, Sabiha; Christopher-Stine, Lisa (2011). "Polymyositis, Dermatomyositis, and Autoimmune Necrotizing Myopathy: Clinical Features". Rheumatic Disease Clinics of North America. 37 (2): 143–158. doi:10.1016/j.rdc.2011.01.001. ISSN 0889-857X.
- ↑ 3.0 3.1 3.2 3.3 Airio, A.; Kautiainen, H.; Hakala, M. (2006). "Prognosis and mortality of polymyositis and dermatomyositis patients". Clinical Rheumatology. 25 (2): 234–239. doi:10.1007/s10067-005-1164-z. ISSN 0770-3198.
- ↑ Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
- ↑ Schiffenbauer, Adam; Faghihi-Kashani, Sara; O’Hanlon, Terrence P.; Flegel, Willy A.; Adams, Sharon D.; Targoff, Ira N.; Oddis, Chester V.; Ytterberg, Steven R.; Aggarwal, Rohit; Christopher-Stine, Lisa; Shamim, Ejaz A.; Dellaripa, Paul F.; Danoff, Sonye K.; Mammen, Andrew; Miller, Frederick W. (2018). "The impact of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis". Seminars in Arthritis and Rheumatism. doi:10.1016/j.semarthrit.2018.02.003. ISSN 0049-0172.
- ↑ Bernatsky, S; Joseph, L; Pineau, C A; Belisle, P; Boivin, J F; Banerjee, D; Clarke, A E (2008). "Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences". Annals of the Rheumatic Diseases. 68 (7): 1192–1196. doi:10.1136/ard.2008.093161. ISSN 0003-4967.
- ↑ 7.0 7.1 7.2 Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
- ↑ Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
- ↑ Bernatsky, S; Joseph, L; Pineau, C A; Belisle, P; Boivin, J F; Banerjee, D; Clarke, A E (2008). "Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences". Annals of the Rheumatic Diseases. 68 (7): 1192–1196. doi:10.1136/ard.2008.093161. ISSN 0003-4967.